Clinical trial

Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or…

NCT00084604 · National Cancer Institute (NCI), NIH · Completed

Key facts

NCT number NCT00084604
Title Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Official title A Multicenter, Open-Label, Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Lead sponsor National Cancer Institute (NCI), NIH
Status Completed
Phase Phase 2
Study type Interventional
Conditions Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer
Intervention type Biological, Drug, Other, Procedure
Interventions irinotecan hydrochloride, bevacizumab, cisplatin, computed tomography, laboratory biomarker analysis
Enrollment 47
Start date Apr 1, 2004
Primary completion Oct 1, 2007
First posted Jun 11, 2004
Last update posted Jun 4, 2013
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies